System in biology leading to cell pathology: stable protein-protein interactions after covalent modifications by small molecules or in transgenic cells.
BACKGROUND
The physiological processes in the cell are regulated by reversible, electrostatic protein-protein interactions. Apoptosis is such a regulated process, which is critically important in tissue homeostasis and development and leads to complete disintegration of the cell. Pathological apoptosis, a process similar to apoptosis, is associated with aging and infection. The current study shows that pathological apoptosis is a process caused by the covalent interactions between the signaling proteins, and a characteristic of this pathological network is the covalent binding of calmodulin to regulatory sequences.


RESULTS
Small molecules able to bind covalently to the amino group of lysine, histidine, arginine, or glutamine modify the regulatory sequences of the proteins. The present study analyzed the interaction of calmodulin with the BH3 sequence of Bax, and the calmodulin-binding sequence of myristoylated alanine-rich C-kinase substrate in the presence of xanthurenic acid in primary retinal epithelium cell cultures and murine epithelial fibroblast cell lines transformed with SV40 (wild type [WT], Bid knockout [Bid-/-], and Bax-/-/Bak-/- double knockout [DKO]). Cell death was observed to be associated with the covalent binding of calmodulin, in parallel, to the regulatory sequences of proteins. Xanthurenic acid is known to activate caspase-3 in primary cell cultures, and the results showed that this activation is also observed in WT and Bid-/- cells, but not in DKO cells. However, DKO cells were not protected against death, but high rates of cell death occurred by detachment.


CONCLUSIONS
The results showed that small molecules modify the basic amino acids in the regulatory sequences of proteins leading to covalent interactions between the modified sequences (e.g., calmodulin to calmodulin-binding sites). The formation of these polymers (aggregates) leads to an unregulated and, consequently, pathological protein network. The results suggest a mechanism for the involvement of small molecules in disease development. In the knockout cells, incorrect interactions between proteins were observed without the protein modification by small molecules, indicating the abnormality of the protein network in the transgenic system. The irreversible protein-protein interactions lead to protein aggregation and cell degeneration, which are observed in all aging-associated diseases.
MalinaLab-Axanton, Tiefenaustr.110, CH-3004 Bern, Switzerland. halinamalina@yahoo.com
Halina Z
HZ
Malina
D000818:Animals; D017209:Apoptosis; D051017:Apoptosis Regulatory Proteins / Q000235:genetics / Q000378:metabolism*; D002461:Cell Line, Transformed; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D011499:Protein Processing, Post-Translational; D015398:Signal Transduction; D049490:Systems Biology
D051017:Apoptosis Regulatory Proteins
Biochem Biophys Res Commun. 1999 Nov 19;265(2):600-5
10558916
Macromol Biosci. 2009 Sep 9;9(9):875-83
19434678
J Biol Chem. 2003 Jan 17;278(3):2058-65
12426317
J Interferon Cytokine Res. 2006 Jan;26(1):53-62
16426148
Eur J Ophthalmol. 1996 Jul-Sep;6(3):250-6
8908429
J Clin Oncol. 2009 Aug 10;27(23):3786-93
19398575
Biochem J. 2002 Feb 15;362(Pt 1):1-12
11829734
Chest. 2009 Jan;135(1):173-180
19136405
Mol Pharmacol. 2001 Dec;60(6):1325-31
11723239
Biochim Biophys Acta. 2003 Jul 9;1628(1):1-10
12850267
FEBS Lett. 1994 Oct 10;353(1):21-4
7926014
Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):781-5
17157445
Biochem Biophys Res Commun. 2003 Oct 17;310(2):646-50
14521960
Clin Chim Acta. 2010 Feb;411(3-4):204-9
19913000
Curr Eye Res. 2009 Apr;34(4):274-81
19373575
Acta Vitaminol Enzymol. 1975;29(1-6):236-9
1244098
Biosci Biotechnol Biochem. 1996 May;60(5):874-6
8704317
Am J Pathol. 1998 Feb;152(2):611-9
9466588
J Neurochem. 2008 May;105(3):982-93
18182052
Curr Drug Metab. 2007 Apr;8(3):225-36
17430111
J Immunol. 2000 May 1;164(9):4812-8
10779789
Nature. 1998 Mar 19;392(6673):289-92
9521324
Front Biosci (Landmark Ed). 2009 Jan 01;14:3128-44
19273262
BMC Ophthalmol. 2002 Apr 05;2:1
11934353
Synapse. 1994 Sep;18(1):27-34
7825121
Trends Mol Med. 2009 Apr;15(4):139-47
19303362
Biochem Pharmacol. 2010 Jan 15;79(2):180-7
19686702
Exp Eye Res. 2004 Sep;79(3):443-5; author reply 447-8
15336509
Blood. 2007 Apr 15;109(8):3351-9
17158233
J Clin Invest. 2006 Dec;116(12):3160-70
17111046
Cancer Res. 1987 May 15;47(10):2594-8
2436751
Blood. 2008 Dec 1;112(12):4598-608
18787223
Circulation. 2004 Jun 1;109(21):2655-71
15173049
Circulation. 2009 Jan 6;119(1):99-106
19103993
Graefes Arch Clin Exp Ophthalmol. 1996 Dec;234(12):723-30
8986443
Toxicol Appl Pharmacol. 1988 Nov;96(2):222-32
2848333
BMC Physiol. 2001;1:7
11459518
BMC Cell Biol. 2004 Apr 06;5:14
15068490
Adv Exp Med Biol. 2003;527:121-5
15206724
Can J Physiol Pharmacol. 2008 Nov;86(11):761-9
19011671
Autophagy. 2009 Jan;5(1):122-4
19001861
Int J Cancer. 2002 Sep 10;101(2):151-5
12209992
Stroke. 2009 Mar;40(3 Suppl):S40-4
19064785
Ann N Y Acad Sci. 2008 Dec;1147:53-60
19076430